Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings

Current Medical Research and Opinion

Volumn 20, Issue 12, 2004, Pages 1883-1893

  Mladsi, Deirdre M ^a   Grogg, Amy L ^b   Irish, William D ^a   Lopez, Rebecca B ^a   Degen, Kathleen ^c   Swann, Alan ^d   Nimsch, Christian T ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c MIDDLESEX HOSPITAL   (United States)

^d University of Texas Mental Sciences Institute   (United States)

Author keywords

Olanzapine; Pharmacy cost; Quetiapine; Risperidone; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG USE; FEMALE; FUNCTIONAL ASSESSMENT; GLOBAL ASSESSMENT OF FUNCTIONING; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL HEALTH CARE; PHARMACY; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STATISTICAL ANALYSIS; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COSTS AND COST ANALYSIS; DIBENZOTHIAZEPINES; DRUG COSTS; FEMALE; HUMANS; INPATIENTS; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA;

EID: 13144283637     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X11510     Document Type: Article

References (47)

1. Spearing MK. Schizophrenia. A detailed booklet that describes symptoms, causes, and treatments, with information on getting help and coping [scientific information and review were provided by David Shore and John K. Hsiao]. National Institute of Mental Health (NIMH). 1999
2. Mauskopf JA, David K, Grainger DL, Gibson PJ. Annual health outcomes and treatment costs for schizophrenia populations. J Clin Psychiatry 1999;60:14-9
3. Guest JF, Cookson RF. Cost of schizophrenia to UK society: an incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 1999;15:597-610
4. American Psychiatric Association (APA). Practice guidelines for the treatment of patients with schizophrenia, 2nd ed. American Psychiatric Association; 2004 http://www.psych.org/psych_pract/treatg/pg/SchizPG-Complete- Feb04.pdf
5. Correll CU, Leucht S, Kane JM. Reduced risk of tardive dyskinesia with second-generation antipsychotics: a systematic review of one-year studies. Am J Psychiatry 2004;161(3):414-25
6. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics part 1: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999;33(1):73-85
7. Revicki, DA. 1999. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr Res 19991;35(Suppl):S101-9
8. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotic olanzapine, quetiapine, risperidone, and sertindole, compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68
9. Sartorius N, Fleischhacker WW, Gjerris A, et al. The usefulness and use of second-generation antipsychotic medications. Curr Opin Psychiatry 2002;15(Suppl 1):S1-S51
10. National Institute of Clinical Excellence (NICE). Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. London: National Institute for Clinical Excellence; 2002 (http://www.nice.org.uk)
11. Mortimer A, Williams P, Meddis D. Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost. J Int Med Res 2003;31(3):188-96
12. Borison RL. Recent advances in the pharmacotherapy of schizophrenia. Harv Rev Psychiatry 1997;4(5):255-71
13. Revicki DA. The new atypical antipsychotics: a review of pharmacoeconomic studies. Expert Opin Pharmacother 2000;1(2):249-60
14. Revicki DA. Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. Curr Opin Investig Drugs 2001;2(1):110-7
15. Hamann J, Leucht S, Kissling W. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry 2003;36(1): 18-26
16. Awad AG, Vorunganti LN. Quality of life and new antipsychotics in schizophrenia: are patients better off?" Int J Soc Psychiatry 1999;45(4):268-75
17. Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics: part II: adverse effects, drug interactions, and costs. Ann Pharmacother 1999;33(2):210-7
18. Stark C, Jones J, Agnew J, Hepburn T. Anti-psychotic drug prescription trends in primary care in Scotland 1994-97. Health Bull (Edinb.) 2000;58(2):96-101
19. Dewa CS, Remington G, Herrmann N, Fearnley J, Goering P. How much are atypical antipsychotics agents being used, and do they reach the population who need them? A Canadian experience. Clin Ther 2002;24(9):1466-76
20. Jerrel JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medication. Schizophr Bull 2002;28(4):589-605
21. Daumit GL, Crum RM, Gullar E, et al. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry 2003;60(2):121-8
22. Kozma CM, Mody SH, Sadik MK. A comparative analysis of risperidone and olanzapine dosing patterns in the South Carolina Medicaid program [poster presentation at the Annual Meeting of the American Psychiatric Association] 1999
23. Ascher-Svanum H, Zhu B, Faries D, Ernst FR. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 200402;3(1):11
24. Lucey JV, Libretto SE. Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis. Ire J Med Sci 2003;172(4):195-201
25. Masand PS, Wang X, Gupta S, Schwartz TL, Virk S, Hameed A. Comparison of risperidone and olanzapine in bipolar and schizoaffective disorder. Prim Care Companion J Clin Psychiatry 2002;4(2):70-3
26. Taylor DM, Wright T, Libretto SE. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS) [UK Investigator Group]. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. J Clin Psychiatry 2003;64(5):589-97
27. Byerly MJ; Weber M; Brooks D; Casey SB; Elliot S; Hawkins J. Cost evaluation of risperidone compared with olanzapine. Psychiatric Services 2003;54(5):742-4
28. Schwartz TL, Saba M, Hardoby W, Virk S, Masand PS. Use of atypical antipsychotics in a Veterans Affairs hospital. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(6):1207-10
29. Kasper S, Jones M. Duchesne I. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. Int Clin Psychopharmacol 2001;16(4):189-96
30. Kelly DL, Nelson MW, Love RC, Yu Y, Conley RR. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Psychiatr Services 2001;52(5):676-8
31. Procyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clin Ther 1998;20:1203-17
32. Rabinowitz J, Lichtenberg P, Kaplan Z. Comparison of cost, dosage and clinical preference for risperidone and olanzapine. Schizophr Res 2000;46:91-6
33. Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL. Olanzapine versus risperidone in the treatment of schizophrenia. Pharmacoeconomics 2003;21:683-97
34. Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Managed Care 1998;4(3):345-55
35. Foster RH, Goa KL. Olanzapine. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1999;15(6):611-40
36. Zhao Z. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Managed Care Interface 2002;15:75-81
37. Fuller MA, Shermock KM, Secic M, Laich JS, Durkin MB. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatr Services 2002;53(7):855-60
38. Johnsrud M, Crismon, Grogg A, Thomson A. Risperidone and olanzapine utilization and expenditures within the Texas Medicaid program [poster]. American Psychiatric Association Annual Meeting, New Orleans, LA; May 2001
39. Grogg AL, Damiano A, Malkin J, Sadik K. Medicaid costs of schizophrenia patients initiating atypical antipsychotics. APA-IPS 2002
40. Nightengale BS, et al. Dosing trends and health care costs from a state medicaid perspective: risperidone vs. olanzapine [poster]. APA; May 1999
41. Edgell WS, Rupnow MF. Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorder and Alzheimer's disease. Manag Care Interface 2003;16(5):64-7
42. Medical economics company. Red Book ™ for Windows®. 2001
43. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Int Med 1997;127:757-63
44. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81
45. Irish W, Neighbors D, Grogg A, et al. Using propensity scores to adjust for treatment selection bias: review of methods plus an extension for use in studies with three or more treatment groups. Poster presentation at the ISPOR Fourth Annual European Congress 2001
46. Hosmer DW, Lemeshow S. Applied logistic regression. New York (NY): John Wiley and Sons, 1989
47. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003;28(Suppl 1):9-26